Last updated: June 23, 2026
Genentech v. Centus Biotherapeutics (2:20-cv-00361) Litigation Summary and Patent/Regulatory Analysis
Executive summary: Genentech, Inc. v. Centus Biotherapeutics Ltd., No. 2:20-cv-00361 (E.D. Texas), is a patent infringement action tied to Centus’ biosimilar program for a Genentech biologic. The case posture is centered on whether Centus’ proposed biologic infringes Genentech’s asserted patents and whether Centus can avoid infringement under non-infringing composition and process arguments. Litigation outcome and current injunction or dismissal status are not stated in the provided input, so no reliable, complete litigation disposition or dates can be provided.
What cannot be produced from the provided input: a correct, complete litigation timeline (complaint, amended complaints, Markman, PTAB/Hatch-Waxman-type procedural events, trial/settlement dates), the asserted patent list, the asserted claims, and the procedural status are required for a litigation summary that is legally useful and accurate. The case caption alone is insufficient to generate those details without risking incorrect statements.
What are the asserted patents and claims in Genentech Inc. v. Centus Biotherapeutics Ltd., 2:20-cv-00361?
A complete answer requires the docket’s complaint and infringement contentions identifying:
- the patent numbers asserted,
- the specific claims and infringement theories,
- the accused products and their formulation/manufacturing attributes,
- and any invalidity contentions.
None of these details are available in the provided prompt.
Which patent families typically anchor Genentech biosimilar suits
Genentech biosimilar cases commonly assert combinations of:
- composition-of-matter or formulation patents covering the active protein and/or excipient system,
- method-of-use or therapeutic use patents tied to indications and dosing regimens,
- and manufacturing/process patents covering characterization attributes, cell culture conditions, or purification steps.
No asserted family mapping for this specific docket can be stated without the complaint or court filings.
Where is Genentech v. Centus Biotherapeutics litigated and what is the procedural posture?
A reliable litigation posture requires:
- the court and division confirmation (only “2:20-cv-00361” is provided),
- assigned judge and magistrate,
- schedule milestones (Rule 16/26 deadlines, claim construction schedule),
- and any dispositive motion rulings.
These specifics are not present in the input.
Common procedural milestones to verify on the docket
- Initial complaint filing date and venue assignment
- Service and answer deadlines
- Rule 12 motion to dismiss outcomes
- Disclosure of infringement contentions and invalidity contentions
- Markman order and claim construction
- Summary judgment motion(s)
- Trial scheduling and any settlement-triggered dismissals
No docket data is available to populate these items.
What does the complaint allege: infringement theories and accused biosimilar product scope?
A useful allegation-level summary must list:
- the accused biologic(s) and dosage forms,
- the specific infringement theories (literal infringement, DOE, inducement/contributory where applicable),
- and the claim chart structure (how Genentech maps each asserted element).
The prompt does not include the complaint’s factual allegations or claim chart references.
Has Centus challenged validity via inter partes review or other mechanisms in 2:20-cv-00361?
A litigation analysis typically includes whether:
- any asserted patents were challenged at PTAB through IPR, PGR, or CBM,
- the PTAB outcome influenced the district court stay or asserted-claim narrowing,
- and whether estoppel applies to barred grounds.
No PTAB docket links or district-court stay/disposition information are provided.
What is the current case outcome: dismissal, settlement, injunction, or final judgment?
A legal and business-grade summary must identify:
- final disposition date,
- whether the court entered permanent injunction, preliminary injunction, or no injunctive relief,
- damages rulings (if any),
- and whether the case settled with covenant-not-to-sue or royalty/licensing terms.
The provided input includes no outcome or settlement terms.
How strong is Genentech’s patent estate in this case?
A strength analysis depends on:
- the asserted patents’ priority dates and expiration schedules,
- prior art landscape,
- claim construction posture,
- and the history of related litigations and PTAB outcomes.
Without asserted patent numbers, filing dates, or claim construction results, no legally grounded strength scoring can be produced.
What risks exist for Centus’ biosimilar launch under FDA pathways given this litigation?
A launch risk assessment needs:
- the FDA reference product and therapeutic area,
- the biosimilar pathway (351(k)) status,
- whether the litigation is tied to “patent dance” timelines or a BLA application,
- and whether a court-ordered injunction blocks approval or commercial launch.
The prompt does not specify the reference product, biosimilar name, FDA submission status, or any injunction.
How does this suit compare with other Genentech biosimilar litigations against competitors?
A credible comparison requires:
- comparable cases (same target reference product),
- shared asserted patent families,
- consistent claim construction outcomes,
- and whether settlements create licensing benchmarks.
No comparator cases, asserted patents, or target biologics are identified in the prompt.
Key Case Data Table (unpopulated due to missing docket content)
| Field |
Required for summary |
Status with provided input |
| Court and judge |
Determines procedural posture and orders |
Not provided |
| Asserted patent numbers |
Core of infringement/validity analysis |
Not provided |
| Asserted claims |
Enables element-by-element mapping |
Not provided |
| Accused Centus biologic |
Defines infringement scope |
Not provided |
| Filing and service dates |
Supports timeline analysis |
Not provided |
| Markman/claim construction |
Drives infringement risk |
Not provided |
| Motions practice |
Shows invalidity or narrowing |
Not provided |
| PTAB filings |
Validity challenge and estoppel |
Not provided |
| Case disposition |
Settlement/injunction/final judgment |
Not provided |
| FDA linkage |
Launch and exclusivity/injunction impact |
Not provided |
Key Takeaways
- This prompt does not include the docket content needed to produce a complete, accurate litigation summary for Genentech, Inc. v. Centus Biotherapeutics Ltd., No. 2:20-cv-00361.
- A business-relevant analysis requires the complaint/answers/infringement contentions, the asserted patent list, and the case disposition or settlement record.
- Without those documents, any attempt to state asserted patents, claim constructions, or outcome dates would be speculative and not suitable for high-stakes decision-making.
FAQs
- What documents on the district court docket are necessary to summarize 2:20-cv-00361 accurately?
- How do settlement terms in Genentech biosimilar cases typically affect launch timing?
- What is the role of claim construction in biosimilar patent infringement suits like this one?
- How does PTAB estoppel change the invalidity landscape in parallel district litigation?
- What FDA approvals or litigation-triggered stays usually govern commercial launch after biosimilar litigation?
References
No sources were cited because the prompt did not include any case filings, patent numbers, docket entries, or FDA linkage details to cite accurately.
